Repository logo
 

Metformin and Cancer, an Ambiguanidous Relationship.

cam.issuedOnline2022-05-19
dc.contributor.authorSkuli, Sarah J
dc.contributor.authorAlomari, Safwan
dc.contributor.authorGaitsch, Hallie
dc.contributor.authorBakayoko, A'ishah
dc.contributor.authorSkuli, Nicolas
dc.contributor.authorTyler, Betty M
dc.contributor.orcidAlomari, Safwan [0000-0002-7595-818X]
dc.contributor.orcidGaitsch, Hallie [0000-0002-6656-607X]
dc.contributor.orcidTyler, Betty M [0000-0001-9800-6969]
dc.date.accessioned2022-05-21T08:00:21Z
dc.date.available2022-05-21T08:00:21Z
dc.date.issued2022-05-19
dc.date.updated2022-05-21T08:00:20Z
dc.description.abstractThe deregulation of energetic and cellular metabolism is a signature of cancer cells. Thus, drugs targeting cancer cell metabolism may have promising therapeutic potential. Previous reports demonstrate that the widely used normoglycemic agent, metformin, can decrease the risk of cancer in type 2 diabetics and inhibit cell growth in various cancers, including pancreatic, colon, prostate, ovarian, and breast cancer. While metformin is a known adenosine monophosphate-activated protein kinase (AMPK) agonist and an inhibitor of the electron transport chain complex I, its mechanism of action in cancer cells as well as its effect on cancer metabolism is not clearly established. In this review, we will give an update on the role of metformin as an antitumoral agent and detail relevant evidence on the potential use and mechanisms of action of metformin in cancer. Analyzing antitumoral, signaling, and metabolic impacts of metformin on cancer cells may provide promising new therapeutic strategies in oncology.
dc.identifier.doi10.17863/CAM.84774
dc.identifier.eissn1424-8247
dc.identifier.issn1424-8247
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/337360
dc.languageen
dc.publisherMDPI AG
dc.subjectmetformin
dc.subjectdiabetes
dc.subjectcancer metabolism
dc.subjectAMPK
dc.subjectPI3K
dc.subjecttherapeutics
dc.subjectdrug repurposing
dc.titleMetformin and Cancer, an Ambiguanidous Relationship.
dc.typeArticle
dcterms.dateAccepted2022-05-12
prism.issueIdentifier5
prism.publicationNamePharmaceuticals (Basel)
prism.volume15
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/ph15050626

Files

Original bundle
Now showing 1 - 3 of 3
No Thumbnail Available
Name:
additional-files.zip
Size:
218.8 KB
Format:
ZIP file
Description:
Supporting information
Licence
https://creativecommons.org/licenses/by/4.0/
No Thumbnail Available
Name:
pharmaceuticals-15-00626.xml
Size:
8.54 KB
Format:
Extensible Markup Language
Description:
Bibliographic metadata
Licence
https://creativecommons.org/licenses/by/4.0/
Loading...
Thumbnail Image
Name:
pharmaceuticals-15-00626-v2.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
https://creativecommons.org/licenses/by/4.0/